Clinical trials: HIV/AIDS
HIV Infection
Comparing Blood Vessel Endothelial Function in HIV-Infected People and Matched HIV-Uninfected People
The blood vessels that carry blood from the heart to the rest of the body are normally capable of relaxing and constricting when needed to provide more or less blood to the body.
- Trial name
- NCT00919724
- Where
- United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Indiana University
Anxiety Disorders, HIV Infections
Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS
The purpose of this study is to evaluate whether escitalopram is safe, well tolerated, and effective in the treatment of HIV-infected patients with generalized anxiety disorder.
- Trial name
- NCT00887679
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Duke University
HCV Coinfection, Liver Disease
deLIVER: Direct Acting Antiviral Effects on the Liver
Open-label, partially-randomized plasma and liver sampling study to assess hepatitis C virus (HCV) kinetics during treatment with two (Sofosbuvir/Velpatasvir) or three (Sofosbuvir/Velpatasvir/Voxilaprevir) direct acting…
- Conditions
- HCV Coinfection, Liver Disease, HIV
- Trial name
- deLIVER (NCT02938013)
- Testing
- Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX], Sofosbuvir/Velpatasvir (SOF/VEL)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Johns Hopkins University
HIV-1 Infection
PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)
Aging with HIV is associated with earlier development of frailty (weakness) or disability, including loss of physical and muscle strength, and walking speed.
- Trial name
- PREPARE (NCT03070223)
- Testing
- Pitavastatin
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 602 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV
Vitamin D HIV Study on Postmenopausal Women
The purpose of this study is to determine the effects of vitamin D on measures of bone health and immune function in HIV infected postmenopausal women.
- Trial name
- NCT01375010
- Testing
- Vitamin D3, Vitamin Supplements
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Columbia University
Aging-related Inflammation in HIV-infected Patients
Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen
Physicians in charge of HIV-infected patients are increasingly being faced to previously unrecognized comorbid conditions such as atherosclerosis and cardiovascular events, loss of renal function, osteopenia/osteoporosis and bone…
- Trial name
- NCT02577042
- Testing
- Raltegravir, PI-based regimen, Atorvastatin
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
HIV-1-infection
Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women
The goals of this clinical study are to learn more about the study drugs, VRC07-523LS, CAP256V2LS, and vesatolimod (VES) and how safe it is in women that have HIV and are on antiretroviral therapy (ART).
- Trial name
- NCT05281510
- Testing
- Vesatolimod, VRC07523LS, CAP256V2LS
- Where
- South Africa
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
Methamphetamine Abuse, HIV/AIDS
The Getting Off App for Methamphetamine-Using Gay and Bisexual Men
A commonly used manualized outpatient methamphetamine intervention for gay and bisexual men, "Getting Off," is being translated into a mobile phone application (i.e., app) available for download through common app marketplaces.
- Trial name
- NCT03884946
- Testing
- Getting Off App
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- Friends Research Institute, Inc.
Acquired Immunodeficiency Syndrome, HIV Infections
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir…
- Trial name
- NCT01565850
- Testing
- D/C/F/TAF, DRV, COBI
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 153 people
- Sponsor
- Gilead Sciences
HIV
Pre-Exposure Prophylaxis in YMSM
This is an exploratory mixed-methods research study that compares an efficacious behavioral HIV-prevention intervention (3MV) alone to the behavioral HIV-prevention intervention combined with a biomedical intervention (PrEP).
- Trial name
- NCT01033942
- Testing
- coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP, Many Men, Many Voices (3MV)
- Where
- 2 sites in United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
Palifermin is a modified version of a naturally occurring human growth factor that is currently approved by the FDA to treat blood cancers.
- Trial name
- NCT00376935
- Testing
- Palifermin
- Where
- 22 sites in United States
- Volunteers
- 99 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Substance-Related Disorders, Substance Use
Siyakhana Peer: Evaluating a Peer Recovery Coach Model to Reduce Substance Use Stigma in South African HIV Care
Alcohol and other drug use is common among people living with HIV in South Africa and is associated with worse engagement in HIV care.
- Conditions
- Substance-Related Disorders, Substance Use, Substance Use Disorders, Stigma, Social
- Trial name
- NCT05907174
- Testing
- Siyakhana - P
- Where
- South Africa
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- University of Maryland, College Park
HIV
HIV Testing at Family Planning Clinics in Mombasa County, Kenya
Location: Family Planning Clinics in Mombasa County, Kenya Introduction: Integration of HIV treatment and prevention with family planning (FP) services is a promising approach for optimizing delivery of comprehensive healthcare…
- Trial name
- NCT02994355
- Testing
- Systems Analysis and Improvement Approach
- Where
- 24 sites in Kenya
- Volunteers
- 24 people
- Sponsor
- University of Washington
Human Immunodeficiency Virus
Pharmacy-based Pre-exposure Prophylaxis
The proposed research will develop a culturally appropriate pharmacy pre-exposure prophylaxis (PrEP) delivery model for black men who have sex with men (BMSM) who live in high poverty, racial minority neighborhoods.
- Trial name
- NCT04393935
- Testing
- Pharmacy Delivered PrEP Intervention
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Emory University
HIV Infections
Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.
Clinical data suggests that the standard dose of the anti-HIV medication, efavirenz (EFV), could be reduced without compromising its effectiveness.
- Trial name
- ENCORE1 (NCT01011413)
- Testing
- Efavirenz 600mg, Efavirenz 400mg
- Where
- Australia
- Volunteers
- 636 people
- Sponsor
- Kirby Institute
HIV/AIDS
Impact of Metformin on Immuno-virologic Parameters in HIV
Non-diabetic, aviremic HIV-infected individuals on antiretroviral therapy (ART) will be randomized to metformin therapy or to observation for 72 weeks.
- Trial name
- NCT04500678
- Testing
- Metformin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Hawaii
Nonalcoholic Fatty Liver Disease, HIV
Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy
A subset of patients with NAFLD that have not been extensively studied are those infected with human immunodeficiency virus (HIV). Currently, there is no FDA approved treatment for NAFLD or NASH.
- Trial name
- ARRIVE (NCT02684591)
- Testing
- Aramchol
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
HIV
Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption
Background: In most people infected with human immunodeficiency virus (HIV), their immune system cannot control HIV infection. They need drugs called combination antiretroviral therapy (cART) to control the HIV.
- Trial name
- NCT02788175
- Testing
- Entyvio (Vedolizumab)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus, Treatment
First in Human Study of TLC-ART 101 (ACTU 2001)
This study is a prospective, open-label, single-site, first-in-human study of a long-acting, injectable combination antiretroviral therapy platform, with a pharmacologically-guided adaptive design for dose escalation…
- Conditions
- Human Immunodeficiency Virus, Treatment, Antiretroviral Therapy
- Trial name
- NCT05850728
- Testing
- TLC-ART
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Washington
HIV Infections
Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents
The purpose of this study was to evaluate the pharmacokinetics, safety, and tolerability of doravirine (also called MK-1439 or DOR) and doravirine/lamivudine/tenofovir disoproxil fumarate (also called MK-1439A or DOR/3TC/TDF) in…
- Trial name
- NCT03332095
- Testing
- Doravirine (DOR), Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF), Antiretroviral (ARV) medications
- Where
- 8 sites in United States, South Africa and 1 more
- Volunteers
- 55 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.